ORBIMED ADVISORS LLC
- SEC CIK
- 0001055951
Latest role at each company
- ETRA Electra Therapeutics, Inc.Director, 10% Owneras of Sep 23, 2026
- BLSM BlossomHill Therapeutics, Inc.Directoras of Aug 12, 2026
- BRVE Braveheart Bio, Inc.Director, 10% Owneras of Aug 11, 2026
- SCTX Scribe Therapeutics, Inc.Directoras of Jul 29, 2026
- SION Sionna Therapeutics, Inc.Directoras of Jul 9, 2026
Show 39 more companies
- ELVN Enliven Therapeutics, Inc.10% Owneras of Jun 24, 2026
- STTK Shattuck Labs, Inc.Directoras of Jun 15, 2026
- QTTB Q32 Bio Inc.Director, 10% Owneras of Jun 1, 2026
- TRAW Traws Pharma, Inc.10% Owneras of Apr 28, 2026
- PRLD Prelude Therapeutics IncDirector, 10% Owneras of Apr 23, 2026
- IMA ImageneBio, Inc.Directoras of Apr 16, 2026
- ACET Adicet Bio, Inc.10% Owneras of Apr 9, 2026
- KROS Keros Therapeutics, Inc.Directoras of Dec 18, 2025
- PMVP PMV Pharmaceuticals, Inc.10% Owneras of Oct 27, 2025
- CIK 0001764974Directoras of Aug 12, 2025
- CRVS Corvus Pharmaceuticals, Inc.Director, 10% Owneras of Jul 1, 2025
- PASG Passage BIO, Inc.10% Owneras of Jun 26, 2025
- NPCE NeuroPace Inc10% Owneras of May 16, 2025
- XTNT Xtant Medical Holdings, Inc.10% Owneras of Apr 14, 2025
- CMPX Compass Therapeutics, Inc.Director, 10% Owneras of Apr 11, 2025
- EWTX Edgewise Therapeutics, Inc.Director, 10% Owneras of Apr 4, 2025
- IRON Disc Medicine, Inc.Directoras of Mar 26, 2025
- MBX MBX Biosciences, Inc.Director, 10% Owneras of Feb 19, 2025
- CIK 0001900520Directoras of Nov 5, 2024
- UPB Upstream Bio, Inc.Director, 10% Owneras of Oct 17, 2024
- SPRY ARS Pharmaceuticals, Inc.Directoras of Aug 28, 2024
- CIK 000160495010% Owneras of Aug 15, 2024
- CIK 0001831363Director, 10% Owneras of Jul 17, 2024
- TELA TELA Bio, Inc.10% Owneras of Jul 2, 2024
- CIK 0001626199Directoras of May 20, 2024
- CIK 0001797768Director, 10% Owneras of Apr 5, 2024
- CIK 0001745020Director, 10% Owneras of Feb 14, 2024
- AVBP ArriVent BioPharma, Inc.Director, 10% Owneras of Jan 31, 2024
- DMRA Damora Therapeutics, Inc.10% Owneras of Aug 17, 2023
- CIK 0001657312Directoras of May 15, 2023
- CIK 0001595585Director, 10% Owneras of Nov 25, 2022
- CIK 0001923840Director, 10% Owneras of Sep 21, 2022
- CIK 000177342710% Owneras of Sep 14, 2022
- CIK 0001290149Director, 10% Owneras of Jul 1, 2022
- ARQT Arcutis Biotherapeutics, Inc.10% Owneras of Jun 28, 2022
- CIK 000178517310% Owneras of Jan 27, 2022
- JANX Janux Therapeutics, Inc.Directoras of Dec 30, 2021
- CIK 0001808158Directoras of Sep 8, 2021
- CIK 0001522860Director, 10% Owneras of Jul 21, 2021
Trades
Every Form 4 that lists ORBIMED ADVISORS LLC as a reporting owner, including filings made jointly with others. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Company | Filed (ET) | Trade date | Insider | Transaction | Shares | Avg price | Value | Shares after | Holding change | Filing |
|---|---|---|---|---|---|---|---|---|---|---|
| MBXMBX Biosciences, Inc. | Sep 17, 20248:13 PM ET | Sep 16, 2024 | ORBIMED ADVISORS LLC and 2 othersDirector, 10% Owner | PPurchaseCommon Stock | +750K | $16.00 | +$12M | 653.79K | New position | SEC |
| SPRYARS Pharmaceuticals, Inc. | Aug 28, 20244:26 PM ET | Aug 26, 2024 | ORBIMED ADVISORS LLC and 2 othersDirector | SSaleCommon Stock | −83.7K | $13.00 | −$1.09M | 0 | −100.0% | SEC |
| SPRYARS Pharmaceuticals, Inc. | Aug 23, 20246:38 PM ET | Aug 21 – Aug 23, 2024 | ORBIMED ADVISORS LLC and 2 othersDirector | SSaleCommon Stock | −868.68K | $13.2361 | −$11.5M | 83.7K | −91.2% | SEC |
| KROSKeros Therapeutics, Inc. | Aug 15, 20245:01 PM ET | Aug 13, 2024 | ORBIMED ADVISORS LLC and 2 othersDirector | SSaleCommon Stock | −250K | $44.01 | −$11M | 119.52K | −67.7% | SEC |
| – | Aug 15, 20244:51 PM ET | Aug 13, 2024 | ORBIMED ADVISORS LLC and 2 others10% Owner | PPurchaseCommon Stock | +500K | $4.00 | +$2M | 252.86K | New position | SEC |
| – | Jul 17, 20248:48 PM ET | Jul 15 – Jul 16, 2024 | ORBIMED ADVISORS LLC and 4 othersDirector, 10% Owner | SSaleCommon Stock | −56.16K | $10.00 | −$561.64K | 755.64K | −6.9% | SEC10b5-1 |
| TELATELA Bio, Inc. | Jul 2, 20244:54 PM ET | Jun 28 – Jul 2, 2024 | ORBIMED ADVISORS LLC and 1 other10% Owner | SSaleCommon Stock | −428.3K | $4.721 | −$2.02M | 2.41M | −15.1% | SEC |
| IRONDisc Medicine, Inc. | Jun 20, 20245:19 PM ET | Jun 17, 2024 | ORBIMED ADVISORS LLC and 3 othersDirector | PPurchaseCommon Stock | +83.33K | $36.00 | +$3M | 235.39K | +54.8% | SEC |
| ELVNEnliven Therapeutics, Inc. | May 20, 20245:00 PM ET | May 16, 2024 | ORBIMED ADVISORS LLC and 2 othersDirector, 10% Owner | SSaleCommon Stock | −1.03M | $22.14 | −$22.88M | 7.66M | −11.9% | SEC |
| CRVSCorvus Pharmaceuticals, Inc. | May 8, 20248:28 PM ET | May 6, 2024 | ORBIMED ADVISORS LLC and 1 otherDirector, 10% Owner | PPurchaseCommon Stock · Derivative | +2.84M | $1.7311 | +$2.5M | 1.4M | – | SEC |
| NPCENeuroPace Inc | May 3, 20245:16 PM ET | May 1 – May 3, 2024 | ORBIMED ADVISORS LLC and 1 other10% Owner | SSaleCommon Stock | −29.21K | $14.0186 | −$409.43K | 3.41M | −0.9% | SEC |
| NPCENeuroPace Inc | Apr 26, 20245:01 PM ET | Apr 24, 2024 | ORBIMED ADVISORS LLC and 1 other10% Owner | SSaleCommon Stock | −1.78K | $14.06 | −$25.04K | 3.44M | −0.1% | SEC |
| NPCENeuroPace Inc | Apr 23, 20246:38 PM ET | Apr 19 – Apr 23, 2024 | ORBIMED ADVISORS LLC and 1 other10% Owner | SSaleCommon Stock | −64.65K | $14.1224 | −$913.06K | 3.44M | −1.8% | SEC |
| NPCENeuroPace Inc | Apr 18, 20245:10 PM ET | Apr 16 – Apr 18, 2024 | ORBIMED ADVISORS LLC and 1 other10% Owner | SSaleCommon Stock | −16.99K | $14.0202 | −$238.23K | 3.5M | −0.5% | SEC |
| NPCENeuroPace Inc | Apr 15, 20245:25 PM ET | Apr 11 – Apr 12, 2024 | ORBIMED ADVISORS LLC and 1 other10% Owner | SSaleCommon Stock | −485K | $14.4867 | −$7.03M | 3.52M | −12.1% | SEC |
| AVBPArriVent BioPharma, Inc. | Jan 31, 20244:12 PM ET | Jan 30, 2024 | ORBIMED ADVISORS LLC and 3 othersDirector, 10% Owner | PPurchaseCommon Stock | +444.44K | $18.00 | +$8M | 1.51M | +41.6% | SEC |
| ACETAdicet Bio, Inc. | Jan 26, 20247:14 PM ET | Jan 25, 2024 | ORBIMED ADVISORS LLC and 7 othersDirector, 10% Owner | PPurchaseCommon Stock | +3.13M | $2.40 | +$7.5M | 1.26M | New position | SEC |
| EWTXEdgewise Therapeutics, Inc. | Jan 25, 20244:28 PM ET | Jan 23, 2024 | ORBIMED ADVISORS LLC and 2 othersDirector, 10% Owner | PPurchaseCommon Stock | +454.55K | $11.00 | +$5M | 14.44M | +3.3% | SEC |
| – | Dec 29, 20234:18 PM ET | Dec 27 – Dec 28, 2023 | ORBIMED ADVISORS LLC and 2 othersDirector | SSaleCommon Stock | −1.55M | $18.5416 | −$28.67M | 264.32K | −85.4% | SEC |
| IRONDisc Medicine, Inc. | Dec 20, 20236:28 PM ET | Dec 18, 2023 | ORBIMED ADVISORS LLC and 3 othersDirector | SSaleCommon Stock | −1.72K | $59.24 | −$102.13K | 0 | −100.0% | SEC |
| IRONDisc Medicine, Inc. | Dec 15, 20236:04 PM ET | Dec 14, 2023 | ORBIMED ADVISORS LLC and 3 othersDirector | SSaleCommon Stock | −433.2K | $56.75 | −$24.58M | 224.41K | −65.9% | SEC |
| IRONDisc Medicine, Inc. | Dec 14, 20235:44 PM ET | Dec 12 – Dec 14, 2023 | ORBIMED ADVISORS LLC and 3 othersDirector | SSaleCommon Stock | −134.2K | $58.8842 | −$7.9M | 727.81K | −15.6% | SEC |
| PMVPPMV Pharmaceuticals, Inc. | Nov 24, 20234:38 PM ET | Nov 22, 2023 | ORBIMED ADVISORS LLC and 2 others10% Owner | SSaleCommon Stock | −87.79K | $2.23 | −$195.76K | 0 | −100.0% | SEC |
| NPCENeuroPace Inc | Oct 4, 20235:36 PM ET | Oct 2 – Oct 3, 2023 | ORBIMED ADVISORS LLC and 1 other10% Owner | SSaleCommon Stock | −8.31K | $9.0749 | −$75.45K | 4M | −0.2% | SEC |
| SPRYARS Pharmaceuticals, Inc. | Aug 31, 20235:26 PM ET | Aug 29, 2023 | ORBIMED ADVISORS LLC and 2 othersDirector | PPurchaseCommon Stock | +500K | $6.20 | +$3.1M | 8.02M | +6.6% | SEC |
| DMRADamora Therapeutics, Inc. | Aug 17, 20234:40 PM ET | Aug 15, 2023 | ORBIMED ADVISORS LLC and 4 others10% Owner | SSaleCommon Stock | −822.68K | $0.75 | −$617.01K | 1.51M | −35.3% | SEC |
| DMRADamora Therapeutics, Inc. | Aug 2, 20235:05 PM ET | Jul 31, 2023 | ORBIMED ADVISORS LLC and 4 others10% Owner | SSaleCommon Stock | −209.4K | $3.00 | −$628.2K | 2.11M | −9.0% | SEC |
| DMRADamora Therapeutics, Inc. | Jul 27, 20234:28 PM ET | Jul 25, 2023 | ORBIMED ADVISORS LLC and 4 others10% Owner | SSaleCommon Stock | −39.2K | $2.92 | −$114.46K | 2.26M | −1.7% | SEC |
| – | Jul 24, 20234:38 PM ET | Jul 20, 2023 | ORBIMED ADVISORS LLC and 1 otherDirector, 10% Owner | PPurchaseCommon Stock | +416.67K | $12.00 | +$5M | 3.1M | +15.5% | SEC |
| – | Jul 19, 20234:15 PM ET | Jul 17, 2023 | ORBIMED ADVISORS LLC and 2 othersDirector, 10% Owner | PPurchaseCommon Stock | +479.93K | $3.05 | +$1.46M | 650.6K | +281.2% | SEC |
| DMRADamora Therapeutics, Inc. | Jul 17, 20234:13 PM ET | Jul 13, 2023 | ORBIMED ADVISORS LLC and 4 others10% Owner | SSaleCommon Stock | −194.7K | $2.40 | −$467.28K | 2.29M | −7.8% | SEC |
| ACETAdicet Bio, Inc. | Jun 29, 20234:46 PM ET | Jun 27, 2023 | ORBIMED ADVISORS LLC and 8 othersDirector, 10% Owner | PPurchaseCommon Stock | +875K | $2.09 | +$1.83M | 748.05K | New position | SEC |
| PASGPassage BIO, Inc. | Jun 29, 20234:42 PM ET | Jun 27 – Jun 28, 2023 | ORBIMED ADVISORS LLC and 1 other10% Owner | PPurchaseCommon Stock | +1.19M | $0.84 | +$1M | 8.03M | +17.4% | SEC |
| PRLDPrelude Therapeutics Inc | May 24, 20235:09 PM ET | May 22, 2023 | ORBIMED ADVISORS LLC and 2 othersDirector, 10% Owner | PPurchaseCommon Stock | +869.57K | $5.75 | +$5M | 10.12M | +9.4% | SEC |
| – | May 15, 20236:07 PM ET | May 11 – May 15, 2023 | ORBIMED ADVISORS LLC and 1 otherDirector | SSaleOrdinary Shares | −482.91K | $20.5795 | −$9.94M | 3.78M | −11.3% | SEC |
| – | May 8, 20235:22 PM ET | May 4 – May 5, 2023 | ORBIMED ADVISORS LLC and 6 othersDirector, 10% Owner | PPurchaseCommon Stock | +1.46M | $2.797 | +$4.09M | 1.37M | New position | SEC |
| – | May 2, 20239:34 PM ET | Apr 28 – May 2, 2023 | ORBIMED ADVISORS LLC and 6 othersDirector, 10% Owner | PPurchaseCommon Stock | +1.41M | $2.6146 | +$3.67M | 794.37K | New position | SEC |
| TELATELA Bio, Inc. | Apr 21, 20235:08 PM ET | Apr 19 – Apr 21, 2023 | ORBIMED ADVISORS LLC and 1 other10% Owner | SSaleCommon Stock | −192K | $9.335 | −$1.79M | 2.84M | −6.3% | SEC |
| DMRADamora Therapeutics, Inc. | Apr 17, 20235:28 PM ET | Apr 13 – Apr 17, 2023 | ORBIMED ADVISORS LLC and 4 others10% Owner | SSaleCommon Stock | −68.48K | $1.8729 | −$128.26K | 2.42M | −2.8% | SEC |
| DMRADamora Therapeutics, Inc. | Apr 12, 20236:44 PM ET | Apr 10 – Apr 12, 2023 | ORBIMED ADVISORS LLC and 4 others10% Owner | SSaleCommon Stock | −67.54K | $1.7969 | −$121.36K | 2.46M | −2.7% | SEC |
| DMRADamora Therapeutics, Inc. | Apr 7, 20234:42 PM ET | Apr 5 – Apr 6, 2023 | ORBIMED ADVISORS LLC and 4 others10% Owner | SSaleCommon Stock | −102.63K | $2.163 | −$221.99K | 2.51M | −3.9% | SEC |
| IRONDisc Medicine, Inc. | Feb 17, 20234:43 PM ET | Feb 15, 2023 | ORBIMED ADVISORS LLC and 3 othersDirector, 10% Owner | PPurchaseCommon Stock | +108.7K | $23.00 | +$2.5M | 299.21K | +57.1% | SEC |
| – | Dec 28, 20225:57 PM ET | Dec 23, 2022 | ORBIMED ADVISORS LLC and 4 othersDirector, 10% Owner | PPurchaseCommon Stock | +137.93K | $7.25 | +$1,000K | 4.88M | +2.9% | SEC |
| – | Dec 27, 20225:38 PM ET | Dec 22 – Dec 23, 2022 | ORBIMED ADVISORS LLC and 1 otherDirector | SSaleOrdinary Shares | −6.14M | $22.1505 | −$136M | 34.09M | −15.3% | SEC |
| – | Nov 29, 20224:36 PM ET | Nov 25, 2022 | ORBIMED ADVISORS LLC and 2 others10% Owner | PPurchaseCommon Stock | +762.38K | $5.25 | +$4M | 5.33M | +16.7% | SEC |
| – | Nov 25, 20228:13 PM ET | Nov 22 – Nov 25, 2022 | ORBIMED ADVISORS LLC and 1 otherDirector, 10% Owner | SSaleCommon Stock | −10.28M | $0.2145 | −$2.21M | 0 | −100.0% | SEC |
| CMPXCompass Therapeutics, Inc. | Nov 10, 20224:44 PM ET | Nov 8, 2022 | ORBIMED ADVISORS LLC and 2 othersDirector, 10% Owner | PPurchaseCommon Stock | +402K | $3.21 | +$1.29M | 15.22M | +2.7% | SEC |
| – | Nov 9, 20224:25 PM ET | Nov 7, 2022 | ORBIMED ADVISORS LLC and 2 othersDirector, 10% Owner | PPurchaseCommon Stock | +192K | $5.21 | +$1M | 16.73M | +1.2% | SEC |
| – | Sep 21, 20226:00 PM ET | Sep 19, 2022 | ORBIMED ADVISORS LLC and 1 otherDirector, 10% Owner | PPurchaseCommon Stock | +300K | $17.00 | +$5.1M | 5.78M | +5.5% | SEC |
| EWTXEdgewise Therapeutics, Inc. | Sep 16, 20224:31 PM ET | Sep 16, 2022 | ORBIMED ADVISORS LLC and 2 othersDirector, 10% Owner | PPurchaseCommon Stock | +484.5K | $10.32 | +$5M | 13.98M | +3.6% | SEC |